tirzepatide for short term weight loss & Metabolic Support Tirzepatide Injections Chicago | XSculpt

AAPS PharmSciTech, 3(2), 1-8

Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and a nested case-control study (Bezin et al., 2023) that reported increased risk for thyroid cancer following GLP-1 RA-based interventions

Institutions need to establish clear, evidence-informed protocols around when to discontinue GLP-1 drugs prior to various types of surgery, how to bridge diabetes therapy, and who to engage

growing real-world safety data from millions of prescriptions Dose escalation : Gradual monthly increases (2.5 mg starting dose) help manage GI tolerability Dosing and Administration Comparison# Mazdutide Dosing# Tirzepatide Dosing# Use Case Recommendations# Choose Mazdutide When:# Hepatic fat reduction is a specific metabolic goal, where glucagon-mediated fat oxidation provides a differentiated mechanism Chinese/Asian market access is relevant, as mazdutide is approved and available in China GLP-1/glucagon dual mechanism is preferred for patients who may benefit from energy expenditure enhancement alongside appetite suppression MASH/metabolic liver disease is a co-occurring condition alongside obesity Choose Tirzepatide When:# Maximum evidence-based weight loss is the goal, with 20.9% demonstrated in SURMOUNT-1 Type 2 diabetes management requires proven glycemic control, with superiority over semaglutide in SURPASS-2 FDA-approved treatment is needed in the US or EU markets Comprehensive dose flexibility is desired across six dose levels for individualized titration Can They Be Combined?# Combining mazdutide with tirzepatide is not rational, as both contain GLP-1R agonist activity

Schurman L, McCarthy AD, Sedlinsky C, et al